FDA approves Entresto (A new Heart Failure Drug):

More Presentations from Naina Mohamed Pakkir Maideen

©  On 07^th July 2015, the U.S. Food and Drug Administration approved Entresto tablets for the treatment of heart failure.

©  Entresto is a crystalline complex composed of 2 molecular moieties…

Ø Sacubitril (Neprilysin inhibitor )

Ø Valsartan (Angiotensin Receptor Blocker)     

Mechanism of Action:

©  Sacubitril blocks the degradation of endogenous vasoactive peptides (ANP, BNP, bradykinin, and Adrenomedullin), by inhibiting Neprilysin enzyme.

©  Valsartan decreases vasoconstriction and sodium retention by blocking the binding of Angiotensin II to the AT 1 receptors (Vascular smooth muscle and the adrenal gland).

Adverse Drug Reactions:

©  The most common ADRs noted in the clinical trial participants being treated with Entresto include Hypotension, Hyperkalemia, Cough, Dizziness and Renal Impairment.

Contraindications:

©  Entresto is contraindicated in patients taking Aliskiren and ACEIs and in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy.

Drug Interactions:

©  Entresto may interact significantly with drugs such asACE Inhibitors, Aliskiren, ARB, Potassium-sparing diuretics, NSAIDsandLithium.

Pregnancy:

©  Use of Entresto should be discontinued as soon as possible, if pregnancy is detected.

Lactation:

©  Use of Entresto or Breastfeeding should be discontinued.